UK/EU Bureau Chief @FierceBiotech
Joined October 2012
- Tweets 10,221
- Following 1,865
- Followers 2,694
- Likes 4,235
772 Photos and videos
14 Jan 2025
Interesting to hear GSK CEO Emma Walmsley say that Big Pharma should "run towards" conversations about vaccine efficacy as the new U.S. admin approaches. My initial writeup of the #JPM2025 session is here...
fiercebiotech.com/biotech/jp…
2
335
13 Dec 2024
For this week's @FierceBiotech podcast, I caught up with @novonordisk's Marcus Schindler to talk about the future of GLP-1s and the lessons he's learned as Chief Scientific Officer
fiercepharma.com/pharma/novo…
2
2
1,910
19 Nov 2024
My dispatch from Day 1 of Jefferies 2024 - where everyone is now making the comparison with JPM (including the bad weather)
19 Nov 2024
Jefferies London Healthcare Conference, which until last year had been a relatively cozy affair, has seemingly become a victim of its own success. Is the meeting the next JPM? fiercebiotech.com/biotech/so…
219
11 Nov 2024
The KarXT crown looks secure in Bristol Myers' hands for a while at least
11 Nov 2024
The drug candidate at the center of AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics has failed a pair of phase 2 trials, dealing a blow to the program and a boost to rival Bristol Myers Squibb. $ABBV
fiercebiotech.com/biotech/ab…
1
1
3
339
22 Oct 2024
While the in vivo program is taking center stage, @editasmed told me work on reni-cel is not being halted, with a “substantive clinical data set” lined up for #ASH24
22 Oct 2024
Editas is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and signing a $238 million biobucks pact, while seeking a partner for its more advanced ex vivo sickle cell disease medicine. fiercebiotech.com/biotech/ed…
1
2,927
16 Oct 2024
Today's news throws a spanner in two programs that CEO John Jacobs had been pointing to as potential growth drivers for the company fiercebiotech.com/biotech/fd…
102
14 Oct 2024
At LSX in April, Gateway Labs' Julie Gilmore told me they planned to "go to geographies where we think we can make a difference.” Now it turns out one of those will be the UK...
fiercebiotech.com/biotech/li…
1
1
2,029
11 Oct 2024
This morning sees another 2 biotechs joining the steady trickle of IPOs. Upstream has upsized its offering while CAMP4 has rebalanced its own $UBP $CAMP
fiercebiotech.com/biotech/up…
2
1
262
2 Sep 2024
Sanofi's head of R&D told me the company will engage with the FDA “as soon as possible” to discuss filing for approval in non-relapsing secondary progressive MS
2 Sep 2024
Sanofi’s tolebrutinib failed 2 out of 3 phase 3 MS trials that read out this morning, but the pharma is still planning an FDA filing fiercebiotech.com/biotech/sa…
1
430
2 Sep 2024
Sanofi’s tolebrutinib failed 2 out of 3 phase 3 MS trials that read out this morning, but the pharma is still planning an FDA filing fiercebiotech.com/biotech/sa…
595
28 Aug 2024
Looks like Bayer's Juergen Eckhardt was right when he told @fierce in June that he wouldn't let the company's restructuring affect their push for oncology innovation
fiercebiotech.com/biotech/ba…
3
109
James Waldron retweeted
7 Aug 2024
.@FierceBiotech editor @GabrielleMasso9 was interviewed on the NYSE floor this morning! She shared insights on Fierce Biotech's Fierce 15 this year, the use of AI and other trends in the biotech market. Her segment starts at the 40:00 mark
7 Aug 2024
Straight from the NYSE floor! Our editor @GabrielleMasso9 shares insights on this year's Fierce 15 and trends in the biotech market. youtube.com/live/R36O23Q92Dw… @NYSE
3
10
601
James Waldron retweeted
30 Jul 2024
Our recently announced partnership with @GSK will develop a portfolio of entirely new medicines and vaccines to address unmet needs initially focused in respiratory and immunology. For more, read this @FierceBiotech piece by @JamesPharma: fiercebiotech.com/biotech/gs…
3
14
2,060
18 Jul 2024
I noticed J&J had removed its Addex-partnered epilepsy drug from its pipeline. Turns out the Big Pharma had lost faith after April's phase 2 fail
fiercebiotech.com/biotech/jj…
1
75
25 Jun 2024
What were the smartest deals in biopharma over the last few years? The @FierceBiotech team run down some of our favs👀
fiercebiotech.com/biotech/sm…
66
James Waldron retweeted
15 May 2024
Great story here from @AGKootenay: "Despite releasing clinical data that included positive phase 3 results, receiving a fast-track designation from the FDA and receiving $10 million in non-dilutive funding, Vaxxinity’s shares still plummeted from the original list price."
15 May 2024
Vaxxinity, which filed to delist from the Nasdaq last month, is choosing radical transparency about the “abusive relationship” that has defined the immunotherapy medicine company’s three-year stint as a public company. fiercebiotech.com/biotech/va…
1
1
808
James Waldron retweeted
15 May 2024
We're growing the Fierce Biotech team! The first position we’re adding is a staff writer. We’re seeking someone with a few years of experience, ideally with a background in biotech writing. 🔗 recruiting.ultipro.com/QUE10…
7
19
4,022
15 May 2024
Great interview by @AGKootenay and a reminder of how brutal the public markets can still be for biotechs
1
204
8 May 2024
BIG story from @maxonwifi about the latest in a series of major changes at Sanofi
8 May 2024
BREAKING: Sanofi CSO Frank Nestle is leaving the company. fiercebiotech.com/biotech/sa…
1
4
340
26 Apr 2024
More great reporting from @maxonwifi on the ongoing fallout from Bristol Myers' step back from cell therapy R&D
26 Apr 2024
I should've known I was racing against @rleuty_biotech this morning, who got the jump on this story.
BMS is closing a Redwood City research site focused on cell therapy and I-O, consolidating the work at a Brisbane hub ~20 miles away.
fiercebiotech.com/biotech/bm…
1
5
635